Pyxis Oncology financials
$2.900.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.0M | $0.00 | $2.8M | $0.00 | $0.00 | $0.00 | $0.00 | $16.1M | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $8.7M | $0.00 | $2.8M | $0.00 | $0.00 | $0.00 | $0.00 | $15.7M | $0.00 | $0.00 |
| Gross margin | — | — | 78.4% | — | 100.0% | — | — | — | — | 97.1% | — | — |
| Operating income | -$26.0M | -$24.4M | -$18.3M | -$23.5M | -$19.8M | -$22.9M | -$40.1M | -$23.8M | -$20.0M | -$5.6M | -$17.8M | -$25.4M |
| Net income | -$25.3M | -$23.3M | -$18.1M | -$22.0M | -$18.4M | -$21.2M | -$35.6M | -$21.2M | -$17.3M | -$3.3M | -$15.6M | -$23.0M |
| Net margin | — | — | −164.0% | — | −650.9% | — | — | — | — | −20.2% | — | — |
| Diluted EPS | $-0.40 | $-0.37 | $-0.29 | $-0.35 | $-0.30 | $-0.35 | $-0.58 | $-0.35 | $-0.29 | $-0.06 | $-0.35 | $-0.56 |
| EBITDA | -$25.7M | -$23.9M | -$15.4M | -$22.9M | -$19.2M | -$22.4M | -$18.6M | -$23.0M | -$19.4M | -$4.5M | -$17.1M | -$24.8M |
| Operating cash flow | -$18.2M | -$26.0M | -$10.4M | -$13.3M | -$17.3M | -$22.5M | -$19.3M | -$14.7M | -$3.0M | -$20.7M | -$15.3M | -$17.6M |
| Free cash flow | -$18.2M | -$26.0M | -$10.4M | -$13.3M | -$17.3M | -$22.5M | -$19.3M | -$14.7M | -$3.0M | -$20.9M | -$15.3M | -$17.6M |
| Diluted shares | 64.0M | 63.5M | 63.0M | 62.6M | 61.9M | 61.0M | 61.3M | 60.7M | 60.5M | 51.3M | 44.5M | 41.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.9M | $5.8M | $15.4M | $8.9M | $10.7M | $12.8M |
| Short-term investments | $14.1M | $35.3M | $51.4M | $67.3M | $78.2M | $92.7M |
| Total debt | $0.00 | $3.0K | $23.0K | $43.0K | $62.0K | $80.0K |
| Total assets | $54.9M | $64.3M | $91.5M | $105.6M | $123.2M | $135.9M |
| Total liabilities | $43.5M | $33.0M | $38.1M | $36.8M | $35.6M | $32.8M |
| Shareholders' equity | $11.4M | $31.3M | $53.4M | $68.8M | $87.6M | $103.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology